Table 7.
Concentration and AUC of PODXL, SCGB1D2, and CA19-9 at each clinical stage of PDAC
| Indicators | State | PDAC stagea | Number | Median (IQR) | AUC (95% CI) |
|---|---|---|---|---|---|
| PODXL | Control | 51 | 0.15 (−1.01–0.86) | Reference | |
| PDAC | 0/I/II | 7 | 8.48 (7.05–18.2) | 0.96 (0.90–1) | |
| III/IV | 16 | 8.74 (7.14–11.42) | 0.96 (0.91–1) | ||
| SCGB1D2 | Control | 51 | 71.09 (13.08–104.50) | Reference | |
| PDAC | 0/I/II | 7 | 124.50 (44.52–553.00) | 0.66 (0.37–0.95) | |
| III/IV | 16 | 254.30 (211.70–661.70) | 0.87 (0.73–1) | ||
| CA19-9 | Control | 51 | 12.70 (0.93–28.41) | Reference | |
| PDAC | 0/I/II | 7 | 50.00 (19.00–161.80) | 0.79 (0.62–0.96) | |
| III/IV | 16 | 125.40 (11.02–624.20) | 0.77 (0.62–0.92) |
Note:
a
Classified according to the classification of the International Union against Cancer.
Abbreviations: AUC, area under the curve; CA19-9, cancer antigen 19-9; CI, confidence interval; IQR, interquartile range; PDAC, pancreatic ductal adenocarcinoma; PODXL, podocalyxin; SCGB1D2, secretoglobin family 1D, member 2.